Round Rock Advisors LLC Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

Round Rock Advisors LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 30.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,344 shares of the biopharmaceutical company’s stock after selling 6,268 shares during the quarter. Round Rock Advisors LLC’s holdings in Pfizer were worth $381,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Wells Trecaso Financial Group LLC lifted its stake in shares of Pfizer by 2.5% in the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 350 shares during the period. Washington Trust Advisors Inc. raised its holdings in Pfizer by 0.7% during the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock worth $1,424,000 after purchasing an additional 360 shares in the last quarter. Cullen Investment Group LTD. boosted its holdings in Pfizer by 0.9% in the 3rd quarter. Cullen Investment Group LTD. now owns 42,677 shares of the biopharmaceutical company’s stock valued at $1,235,000 after purchasing an additional 377 shares in the last quarter. PSI Advisors LLC increased its position in Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 385 shares during the period. Finally, Western Pacific Wealth Management LP raised its stake in shares of Pfizer by 10.5% during the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 386 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Price Performance

Pfizer stock opened at $26.51 on Friday. The stock has a market capitalization of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm’s 50-day moving average is $26.27 and its two-hundred day moving average is $27.86.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is presently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.